[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353059-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-353059-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","local-delivery-of-sbrt-and-il-12-to-murine-pdac-tumors-modulates-hematopoiesis","Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis","","Local delivery of targeted stereotactic body radiation therapy (SBRT) combined with intratumoral interleukin-12 (IL-12) mRNA was assessed in a murine pancreatic ductal adenocarcinoma (PDAC) model. Tumor, blood, and bone marrow compartments were analyzed across a 13-day to 13-month period. Although SBRT/IL-12 eradicated primary tumors locally, it produced substantial distal bone-marrow effects, including early acute lymphopenia, increased hematopoiesis, later reduction of hematopoietic stem cells, and myeloid-skewing consistent with premature HSC aging.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/local-delivery-of-sbrt-and-il-12-to-murine-pdac-tumors-modulates-hematopoiesis/353059/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/local-delivery-of-sbrt-and-il-12-to-murine-pdac-tumors-modulates-hematopoiesis/353059.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What therapies were delivered locally in the murine PDAC model?","Question",{"text":63,"@type":64},"Tumors were treated with targeted stereotactic body radiation therapy (SBRT) together with intratumoral IL-12 mRNA.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What early systemic hematologic effect was observed after SBRT/IL-12?",{"text":68,"@type":64},"Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow that increased hematopoiesis.",{"name":70,"@type":61,"acceptedAnswer":71},"How did long-term bone marrow changes relate to hematopoietic stem cells?",{"text":72,"@type":64},"Long-term effects included reduced hematopoietic stem cells and a shift toward a myeloid lineage, suggesting potential premature aging of the HSC population.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},353059,1790168380,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","ONCOIMMUNOLOGY  \n2026, VOL. 15, NO. 1, 2682058  \n[https://doi.org/10.1080/2162402X.2026.2682058](https://doi.org/10.1080/2162402X.2026.2682058)  \nRESEARCH ARTICLE     \nLocal delivery of SBRT and IL-12 to murine PDAC tumors modulateshematopoiesis  \nTara G. Vroomana, b,c,d, 1, Emily R. Quaratoc,e, 1, Gary Hannona, b,c, 1 , Noah A. Salamac,d,  \nMaggie L. Lescha, b,c,d, Angela L. Hughsona, b,c, Vedika S. Chandaka, b,c, Nataliia Vdovichenkoc,f, Zhiming Jinc,g, Ronald Lakonyc, Jian Yea, b,c, Sarah L. Eckla, b,c,d, Sidney Lessera, b,c, Edith M. Lordb,c,d, David C. Linehana, b,c, Haoming Qiuh, Nadia Luheshii, Jim Eylesi, Laura M. Calvic,f and  \nScott A. Gerbera, b,c,d, h  \naDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA; bCenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, NY, USA; cWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA; dDepartment of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, USA; eDepartment of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA; fDepartment of Medicine, University of Rochester Medical Center, Rochester, NY, USA; gDepartment of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA; hDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA; iOncology R&D, AstraZeneca, The Discovery Center, Cambridge Biomedical Campus, Cambridge, UK  \nABSTRACT  \nStandard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC) . Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such asthe bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12) . We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.  \nARTICLE HISTORY  \nReceived 04 March 2025 Revised 29 December 2025 Accepted 26 May 2026  \nKEYWORDS  \nPancreatic ductaladenocarcinoma;  \nhematopoietic stem cells; stereotactic body radiation therapy; interleukin-12, bone marrow; hematopoiesis  \nIntroduction  \nImmunotherapy is an emerging cancer treatment that harnesses the body's immune system to recognize and destroy cancer cells, offering a promising alternative to traditional cytotoxic therapies like chemotherapy and radiation. Systemically administered immunotherapies have transformed cancer treatment, particularly through durable responses seen with immune checkpoint inhibitors (ICIs) in various advanced malignancies. 1 However, many patients do not respond to these therapies due to multiple tumor resistance mechanisms.2 Additionally, systemic immunotherapy is hampered by dose-limiting toxicities, restraining treatment efficacy.3 Localized delivery can circumvent these barriers, allowing for higher concentrations of the therapeutic agent at the tumor site while also minimizing toxicity.4 Interleukin","cbCaihErabCtFea8","https://ap.wps.com/l/cbCaihErabCtFea8","pdf",3337176,18,"English","# Abstract\n# Introduction\n## Background: immunotherapy and systemic toxicity\n## Rationale for localized delivery\n## IL-12 delivery and remaining knowledge gaps","[{\"question\":\"What therapies were delivered locally in the murine PDAC model?\",\"answer\":\"Tumors were treated with targeted stereotactic body radiation therapy (SBRT) together with intratumoral IL-12 mRNA.\"},{\"question\":\"What early systemic hematologic effect was observed after SBRT/IL-12?\",\"answer\":\"Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow that increased hematopoiesis.\"},{\"question\":\"How did long-term bone marrow changes relate to hematopoietic stem cells?\",\"answer\":\"Long-term effects included reduced hematopoietic stem cells and a shift toward a myeloid lineage, suggesting potential premature aging of the HSC population.\"}]","Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis | PDF",1790102788,45,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3cae78df345a3e5a40ad9b45e173317c.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc8a62ef05576e8363939229fff75b8a.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad76ad539d624504cbcdc35743ee8cce.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ee982301bf6b038bbf6e4aea925c1a2.webp",980,1306]